Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab
Comprehensive insights on the clinical management of adverse events from talquetamab seen in patients with multiple myeloma, including cytokine release syndrome and infections.
This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
For cytokine release syndrome (CRS) management with tocilizumab, Mount Sinai Health System in New York, New York, employs early intervention with tocilizumab at initial fever onset, avoiding corticosteroids initially. Memorial Sloan Kettering Cancer Center in New York, New York, also uses early tocilizumab trigger at first fever, having overcome hesitancy from chimeric antigen receptor T-cell therapy experience given lack of efficacy impact.
Regarding infection prophylaxis with talquetamab, varicella-zoster virus and Pneumocystis jirovecii pneumonia prophylaxis are used, with little other antimicrobial prophylaxis unless prior infection directs tailored approaches. Some differences persist in GPRC5D infectious risk precaution vs BCMA regimens.
Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
